Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated Patients

Recruiting N/A Interventional Study
ARG1 Deficiency
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
0 – 100
Sex
Any
Study type
Interventional
Purpose
Other
Participants needed
100 (estimated)
Sponsor
Immedica Pharma US Inc · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Arginase 1 deficiency (ARG1-D) is a rare condition in which the body cannot properly break down a substance called arginine. This leads to high levels of arginine and related substances in the blood, which can cause serious health problems and reduce quality of life. Loargys is a new treatment designed to lower arginine levels in people with ARG1-D. It works by providing a modified version of a n…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Participant receiving treatment with commercialized Loargys for ARG1-D * Participant is willing to sign the Informed Consent Form Exclusion Criteria: * None
Contacts

Head of Global Integrated Evidence Generation

+46(0)853339500

clinical@immedica.com

CONTACT